respiratori
complic
particular
infect
common
set
hematolog
malign
hematopoet
stem
cell
transplant
symptom
nonspecif
therefor
difficult
identifi
treat
caus
howev
understand
specif
immun
defect
clinic
paramet
speed
onset
radiolog
find
allow
logic
diagnost
treatment
plan
made
radiolog
find
includ
consolid
nodul
diffus
chang
ground
glass
treeinbud
chang
common
infect
induc
symptom
includ
bacteri
pneumonia
invas
fungal
diseas
pneumocysti
jirovecii
respiratori
virus
infect
must
differenti
inflammatori
complic
often
requir
immun
suppress
treatment
diagnosi
refin
aid
investig
bronchoscopi
comput
tomographi
ct
guid
lung
biopsi
cultur
serolog
test
articl
give
schema
approach
patient
respiratori
symptom
patient
group
howev
common
scenario
rapidli
deterior
patient
treatment
often
begin
empir
aim
deescal
treatment
subsequ
target
investig
hematolog
malign
rel
common
preval
per
approxim
case
unit
kingdom
one
time
consist
heterogen
group
diseas
treat
high
dose
chemotherapi
often
follow
hematopoet
stem
cell
transplant
hsct
diseas
well
treatment
lead
signific
immunosuppress
leav
patient
suscept
infect
often
affect
respiratori
system
consequ
approxim
patient
hematolog
malign
develop
respiratori
infect
cours
treatment
although
articl
focus
infect
complic
hematolog
malign
noninfecti
disord
account
approxim
half
respiratori
complic
post
hsct
must
alway
activ
consid
differenti
diagnosi
tabl
show
common
seriou
noninfecti
problem
aris
post
hsct
treatment
noninfecti
disord
often
requir
increas
immunosuppress
signific
infect
usual
exclud
prior
commenc
treatment
noninfecti
pulmonari
complic
hematolog
diseas
organ
caus
infect
reach
lung
varieti
sourc
pathogen
includ
common
gram
posit
neg
pathogen
staphylococcu
aureu
pseudomona
aeruginosa
respect
well
anaerob
see
tabl
mani
bacteri
pathogen
nasopharyng
commens
immunosuppress
individu
less
abl
effect
clear
lung
aspir
respiratori
ground
glass
peribronchi
crazi
pave
reticul
tractionbronchiectasi
pathogen
also
commonli
inhal
infect
contact
droplet
spread
commonest
caus
organ
group
respiratori
virus
see
tabl
usual
caus
mild
selflimit
infect
immunocompet
individu
patient
hematolog
malign
present
rel
sever
symptom
prolong
infect
higher
rate
pneumonia
death
less
common
caus
inhal
droplet
lung
infect
mycoplasma
pneumonia
chlamydia
pneumonia
mycobacterium
tuberculosi
tabl
inhal
environment
organ
usual
caus
infect
immunocompet
host
anoth
signific
sourc
respiratori
infect
includ
aspergillu
speci
filament
fungi
nocardia
nontubercul
mycobacteria
aspergillu
particular
affect
patient
hematolog
malign
immunosuppress
associ
hematolog
malign
may
also
allow
reactiv
organ
either
dormant
persist
low
number
within
lung
pathogen
includ
pneumocysti
jirovecii
seem
lung
commens
replic
caus
diseas
certain
type
immunosuppress
unless
patient
given
appropri
prophylaxi
reactiv
also
mode
infect
pneumon
caus
cytomegaloviru
cmv
herp
virus
case
tuberculosi
occur
subject
latent
infect
final
infect
part
bodi
spread
lung
via
hematogen
spread
exampl
candida
speci
bacteri
seed
septic
emboli
indwel
cathet
line
multipl
potenti
infect
organ
correspond
varieti
antimicrobi
treatment
option
make
select
appropri
manag
strategi
difficult
fortun
understand
specif
immun
defici
act
specif
risk
factor
specif
organ
tabl
combin
clinic
paramet
speed
onset
tabl
radiolog
appear
usual
allow
differenti
diagnosi
narrow
turn
allow
format
logic
target
diagnost
treatment
plan
patient
improv
rapidli
firstlin
therapi
broad
spectrum
antibiot
crosssect
thorac
ct
imag
essenti
provid
much
better
definit
pattern
radiolog
chang
chest
radiograph
radiolog
pattern
broken
three
main
group
consolid
nodul
microand
macro
diffus
chang
subdivid
ground
glass
treeinbud
pattern
discuss
like
caus
radiolog
pattern
guid
appropri
initi
investig
treatment
option
dens
focal
consolid
fig
often
develop
rapidli
context
fever
dyspnoea
elev
creactiv
protein
crp
clinic
pattern
highli
suggest
pneumonia
caus
pyogen
bacteri
pathogen
associ
commun
hospit
acquir
pneumonia
often
origin
microaspir
nasopharyng
commens
blood
sputum
cultur
essenti
treatment
broadspectrum
antibiot
incorpor
gram
neg
cover
commenc
patient
respond
make
invas
investig
bronchoscopi
unnecessari
howev
patient
respond
rapidli
within
hour
infect
highli
resist
organ
methicillinresist
aureu
multiresist
p
aeruginosa
resist
three
follow
carbapenem
ceftazidim
tobramycin
ciprofloxacin
consid
necessit
escal
secondlin
antibiot
patient
toler
bronchoscopi
bronchoalveolar
lavag
bal
affect
lobe
perform
tri
obtain
clear
microbiolog
diagnosi
focal
consolid
subacut
onset
broader
differenti
diagnosi
includ
bacteri
pneumonia
aspergillu
speci
nocardia
speci
usual
asteroid
noninfecti
caus
organ
pneumonia
recurr
hematolog
malign
diagnost
test
includ
bal
cultur
galactomannan
cytolog
necessari
transbronchi
biopsi
low
yield
recommend
diagnosi
invas
fungal
diseas
given
complic
rate
pneumothorax
particular
may
use
confirm
altern
diagnos
dens
peripher
lesion
adjac
pleura
amen
ct
guid
percutan
biopsi
histolog
rapidli
confirm
diagnosi
invas
fungal
diseas
ifd
nocardia
infect
organ
pneumonia
malign
infiltr
eg
lymphoma
biopsi
materi
also
sent
cultur
pulmonari
nodul
round
lesion
within
lung
diamet
greater
mm
diamet
hematolog
malign
popul
often
substanti
larger
term
macronodul
presenc
macronodul
alway
rais
suspicion
ifd
commonest
invas
aspergillosi
major
caus
fumigatu
sever
aspergillu
filament
fungi
speci
mucormycet
caus
ifd
similar
clinic
radiolog
find
ct
scan
sever
distinct
appear
increas
likelihood
macronodul
caus
ifd
though
necessarili
specif
surround
halo
ground
glass
fig
classic
sign
angioinvas
fungal
diseas
halo
repres
hemorrhag
air
crescent
sign
fig
due
format
fungal
ball
within
caviti
caus
fungal
destruct
lung
tissu
also
highli
suggest
ifd
macronodul
caus
ifd
undergo
classic
evolut
chang
ct
infect
control
nodul
develop
air
crescent
sign
follow
thin
caviti
wall
shrinkag
overal
size
associ
clearanc
associ
surround
consolid
recent
describ
ct
sign
point
ifd
occlud
vessel
sign
pulmonari
arteri
interrupt
within
area
consolid
sensit
specif
proven
probabl
ifd
eortc
criteria
requir
ct
pulmonari
angiogram
protocol
contrast
inject
attend
risk
renal
toxic
allerg
reaction
similarli
hypodens
sign
central
hypoattenu
within
macronodul
recent
shown
similar
sensit
superior
specif
halo
sign
ifd
revers
halo
also
term
atol
sign
strong
indic
mucormycosi
earli
diseas
cours
neutropen
patient
although
ct
appear
macronodul
highli
suggest
ifd
microbiolog
confirm
give
addit
confid
diagnosi
ensur
patient
receiv
antifung
treatment
effect
specif
infect
fungal
pathogen
unfortun
exist
microbiolog
test
ifd
signific
drawback
cultur
bal
sputa
insensit
although
posit
immunosuppress
patient
highli
suggest
activ
infect
antigen
test
use
serum
galactomannan
sensit
specif
two
sequenti
sampl
optic
densiti
give
neg
predict
valu
azol
naiv
patient
highest
risk
group
neutropen
patient
confirm
ifd
speci
furthermor
serum
galactomannan
less
accur
patient
receiv
triazol
prophylaxi
widespread
use
hematooncolog
patient
measur
galactomannan
bal
instead
much
greater
sensit
specif
even
set
triazol
prophylaxi
henc
neg
bal
galactomannan
allow
deescal
treatment
antifung
mucormycet
littl
galactomannan
cell
wall
render
serum
bal
analysi
test
insensit
aspergillu
polymeras
chain
reaction
pcr
sensit
may
specif
due
widespread
presenc
aspergillu
speci
environ
yet
littl
standard
kit
widespread
use
later
flow
devic
provid
point
care
test
fungal
wall
antigen
sensit
specif
pcr
signific
clinic
promis
yet
wide
commerci
use
discuss
consolid
section
ct
guid
percutan
biopsi
rapid
way
identifi
ifd
macronodul
well
pathogen
noninfect
diagnos
biopsi
materi
also
sent
cultur
identifi
infect
speci
antimicrobi
resist
profil
hemorrhag
pneumothorax
main
complic
percutan
ct
guid
biopsi
former
particular
problem
hematolog
malign
due
preval
signific
thrombocytopenia
howev
target
peripher
lesion
use
platelet
transfus
minim
risk
overal
specif
diagnosi
invas
fungal
diseas
difficult
achiev
microbiolog
diagnosi
ifd
remain
unreli
diagnosi
usual
made
consider
multipl
element
clinic
risk
factor
radiolog
chang
biomark
use
triazol
prophylaxi
mortal
without
treatment
high
empir
treatment
usual
start
highrisk
patient
soon
clinic
pictur
compat
ifd
although
publish
data
suggest
azol
voriconazol
posaconazol
effect
amphotericin
liposom
amphotericin
often
firstlin
therapi
patient
receiv
azol
prophylaxi
due
fear
fungal
resist
azol
use
ensur
therapeut
level
achiev
monitor
serum
level
improv
outcom
newer
azol
develop
one
isavuconazol
recent
shown
noninferior
voriconazol
advantag
effect
mucormycosi
dual
agent
antifung
may
superior
outcom
ifd
could
consid
critic
ill
patient
caus
nodul
includ
septic
emboli
nocardia
mycobacteri
infect
noninfecti
caus
septic
bacteri
emboli
caus
distinct
radiolog
appear
multipl
cavit
nodul
usual
lung
peripheri
often
erod
pleural
space
caus
infect
hydropneumothorac
common
sourc
infect
indwel
cathet
line
infect
need
consid
patient
radiolog
evid
lung
nodul
necessit
pair
blood
line
cultur
multipl
welldefin
micronodul
context
cellmedi
immun
defici
caus
nocardia
mycobacteri
speci
nocardi
infect
associ
myeloabl
condit
steroid
median
time
infect
month
post
hsct
pulmonari
infect
mortal
rate
requir
treatment
month
oral
trimethoprimsulphamethoxazol
parenter
treatment
carbapenem
andor
amikacin
prophylact
trimethoprimsulphamethoxazol
pneumocysti
also
protect
nocardia
nontubercul
mycobacteria
infect
post
hsct
incid
associ
gvhd
immunosuppress
mortal
rate
noninfecti
caus
nodul
lymphoma
malign
post
transplant
lymphoprolif
disord
ptld
need
histolog
diagnosi
howev
smaller
size
nodul
may
amen
percutan
biopsi
yield
bal
remain
poor
nonrespond
patient
diagnosi
may
requir
video
assist
thoracoscop
biopsi
situat
import
tri
identifi
potenti
extrathorac
site
diseas
amen
biopsi
lung
differenti
diagnosi
diffus
less
dens
bilater
infiltr
ct
scan
broad
chang
encompass
two
main
pattern
ground
glass
infiltr
treeinbud
chang
differ
like
caus
discuss
separ
import
microbiolog
test
blood
sputum
cultur
serum
antigen
test
fungal
cell
wall
compon
blood
cmv
viral
load
multiplex
pcr
respiratori
virus
nasopharyng
aspir
inflammatori
marker
crp
help
differenti
infecti
noninfecti
caus
although
crp
also
significantli
elev
noninfect
hyperinflammatori
state
serial
full
blood
count
coagul
statu
help
identifi
patient
risk
engraft
syndrom
clinic
syndrom
occur
time
neutrophil
recoveri
pulmonari
hemorrhag
obtain
bal
cytolog
microbiolog
test
help
patient
often
hypox
undergo
bronchoscopi
bilater
ground
glass
infiltr
fig
caus
wide
rang
microbi
pathogen
includ
pyogen
bacteria
respiratori
virus
cytomegaloviru
pneumocysti
jirovecii
multipl
noninfect
caus
pattern
unlik
caus
ifd
often
ground
glass
infiltr
associ
area
denser
consolid
creat
mix
appear
ct
scan
like
caus
rapid
onset
bilater
ground
glass
infiltr
day
includ
bacteri
infect
pulmonari
edema
acut
respiratori
distress
syndrom
ard
less
commonli
alveolar
hemorrhag
engraft
syndrom
engraft
syndrom
present
widespread
infiltr
associ
fever
rash
organ
dysfunct
within
day
granulocyt
recoveri
posthsct
subacut
onset
respiratori
symptom
day
week
associ
ground
glass
chang
similar
caus
acut
present
differenti
diagnosi
need
expand
includ
p
jirovecii
cmv
respiratori
virus
drugor
radiotherapyinduc
pneumon
aspect
clinic
present
diseas
suggest
underli
caus
discuss
pneumocysti
pneumonia
pjp
previous
refer
pcp
older
public
often
distinct
clinic
present
progress
dyspnoea
sever
week
associ
desatur
exert
eventu
hypoxemia
usual
associ
lowgrad
fever
moder
increas
crp
incid
low
patient
receiv
prophylaxi
pulmonari
coinfect
common
particularli
cmv
mortal
rate
report
high
hematolog
malign
although
experi
consider
less
ct
find
often
highli
suggest
pjp
classic
show
diffus
bilater
ground
glass
shadow
predilect
upper
lobe
mark
subpleur
spare
serum
antigen
test
help
publish
sensit
specif
pjp
howev
level
also
elev
fungi
particular
candidemia
need
interpret
context
overal
clinic
pictur
diagnosi
pjp
also
confirm
patient
identif
cyst
bronchoalveolar
lavag
use
immunofluoresc
although
often
neg
hematolog
patient
overal
patient
classic
clinic
radiolog
present
diagnosi
pjp
confirm
respons
empir
treatment
usual
high
dose
cotrimoxazol
clindamycin
primaquin
adjunct
system
corticosteroid
use
hypox
patient
complic
assess
respons
empir
treatment
noninfect
caus
pneumon
also
improv
corticosteroid
treatment
cmv
pneumon
often
due
reactiv
latent
infect
period
impair
cell
mediat
immun
tcell
deplet
rather
primari
infect
high
mortal
ct
find
cmv
pneumonia
distinct
includ
bilater
ground
glass
infiltr
symmetr
micronodul
diagnosi
suggest
highli
elev
blood
cmv
viral
load
especi
increas
rapidli
confirm
obtain
bal
fluid
quantit
pcr
cytolog
look
viral
inclus
bodi
howev
patient
often
hypox
safe
bronchoscopi
treatment
intraven
ganciclovir
follow
convers
valganciclovir
foscarnet
cidofovir
second
third
line
agent
although
clinic
eg
rapid
weight
gain
suggest
fluid
retent
pulmonari
oedema
radiolog
featur
tabl
suggest
specif
caus
make
confirm
diagnosi
noninfect
etiolog
bilater
infiltr
often
difficult
diagnosi
often
partial
depend
microbiolog
test
tri
exclud
infect
caus
includ
bronchoscopi
patient
abl
toler
procedur
bronchoscopi
also
diagnost
alveolar
hemorrhag
similar
increas
recoveri
bloodi
fluid
sequenti
lavag
main
clinic
decis
whether
introduc
system
corticosteroid
treatment
suspect
noninfect
caus
drugor
radiationpneumon
alveolar
hemorrhag
rarer
complic
specif
therapi
alltran
retino
acid
differenti
syndrom
bilater
treeinbud
fig
chang
suggest
acut
respiratori
viral
infect
tabl
widespread
bacteri
bronchiol
sometim
seen
patient
bronchiectasi
complic
hematolog
diseas
eg
secondari
hypogammaglobulinemia
respiratori
viral
infect
common
patient
hematolog
diseas
readili
diagnos
pcr
nasopharyng
aspir
ct
often
demonstr
widespread
diffus
symmetr
treeinbud
chang
although
infect
also
caus
ground
glass
infiltr
comparison
immunocompet
individu
respiratori
viral
infect
patient
hematolog
malign
particularli
hsct
prolong
last
week
even
month
lead
increas
risk
respiratori
compromis
due
develop
viral
secondari
bacteri
pneumonia
virus
recognis
caus
respiratori
infect
hematooncolog
patient
note
tabl
specif
treatment
though
data
efficaci
larg
limit
case
seri
ribavirin
use
respiratori
syncyti
viru
rsv
although
appear
littl
effect
patient
develop
respiratori
failur
adenoviru
often
cultur
though
less
commonli
caus
infect
treat
cidofovir
neuraminidas
inhibitor
reduc
mortal
due
influenza
infect
although
less
effect
patient
immunosuppress
gvhd
lymphopenia
older
age
preemptiv
vaccin
key
prevent
infect
recogn
organismspecif
treatment
parainfluenza
human
metapneumoviru
rhinoviru
bronchiectasi
common
complic
mani
hematolog
diseas
includ
multipl
myeloma
chronic
lymphocyt
leukemia
cll
bcell
deplet
therapi
hsct
result
subacut
bacteri
bronchial
infect
caus
patchi
treeinbud
infiltr
associ
bronchial
wall
thicken
dilat
usual
caus
gram
neg
pathogen
k
pneumonia
p
aeruginosa
requir
prolong
therapi
appropri
antibiot
short
antibiot
cours
allow
infect
recur
lead
viciou
cycl
recurr
infect
inabl
gain
weight
fulli
recov
next
infect
occur
antibiot
prophylaxi
correct
hypogammaglobulinemia
supplementari
immunoglobulin
import
patient
also
recommend
patient
hematolog
malign
secondari
antibodi
defici
set
recurr
infect
almost
hematolog
patient
present
acut
fever
dyspnoea
requir
broadspectrum
antibiot
start
antifung
initi
fever
improv
outcom
compar
delay
day
fever
settl
similarli
crosssect
ct
necessari
symptom
resolv
rapidli
antibiot
fever
persist
characterist
ct
chang
clinic
context
speed
onset
immun
defect
clinic
featur
often
indic
need
specif
treatment
exampl
liposom
amphotericin
voriconazol
neutropen
patient
macronodul
surround
halo
howev
wide
differenti
diagnosi
mean
empir
treatment
target
differ
infecti
noninfecti
caus
often
requir
microbiolog
confirm
remain
variabl
success
cultur
techniqu
slow
sensit
poor
henc
develop
biomark
pcr
increas
sensit
invas
procedur
bronchoscopi
biopsi
give
vital
diagnost
inform
particular
allow
deescal
antifung
make
altern
diagnos
patient
deterior
rapidli
hypox
investig
furthermor
mani
case
respiratori
problem
hematolog
patient
combin
caus
even
microb
identifi
may
prevent
broader
treatment
anoth
signific
issu
stop
therapi
patient
treat
empir
multipl
agent
improv
caus
underli
problem
may
remain
unclear
bacteri
infect
resolv
day
antibiot
aspergillosi
requir
prolong
therapi
prevent
recurr
exactli
long
antifung
continu
known
serum
galactomannan
level
may
util
reduct
week
associ
good
clinic
outcom
mainli
outcom
monitor
observ
radiolog
respons
unclear
stage
evolut
safe
stop
antifung
without
lead
signific
risk
recurr
patient
hematolog
malign
develop
rang
immun
defect
cours
ill
associ
necessari
treatment
allow
variou
pathogen
caus
diseas
respiratori
tract
commonli
affect
associ
signific
morbid
mortal
infect
must
treat
promptli
requir
empir
therapi
chosen
cover
like
pathogen
given
clinic
present
understand
relev
immun
defect
along
recognit
pattern
clinic
present
find
crosssect
ct
imag
allow
logic
deduct
like
culprit
target
microbiolog
molecular
investig
help
narrow
differenti
diagnosi
caveat
signific
crossov
radiolog
find
high
preval
noninfect
respiratori
complic
often
diagnos
exclus
mani
occas
specif
diagnosi
never
discov
critic
ill
patient
treat
multipl
organ
noninfect
complic
empir
urgent
need
improv
rapid
diagnost
better
sensit
specif
allow
direct
treatment
respiratori
infect
hematolog
malign
ideal
futur
research
focu
develop
point
care
test
accur
identifi
specif
organ
possibl
noninvas
easi
perform
even
critic
ill
patient
allow
pathogenspecif
treatment
minimis
unnecessari
drugrel
toxic
